07/03/25
Clinical trial shows potential for treating glaucoma and diabetic retinopathy
Two phase 2a clinical trials showed positive results for the PER-001 intravitreal implant as the first disease-modifying treatment for glaucoma and diabetic retinopathy (DR). In assessing these results, Dr. Joel Schuman, co-director of the Wills Eye Glaucoma Service, noted that "the current study results are most encouraging, demonstrating the potential for a radically new, transformational treatment approach for this disease." There are plans to initiate pivotal phase 2b/3 trials with a larger population of patients over a longer period, starting in the second half of 2025.